EP1440973A3
(en)
|
1995-11-17 |
2004-10-20 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Epothilone derivatives, preparation and use
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US5969145A
(en)
*
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
DE19636343C1
(en)
*
|
1996-08-30 |
1997-10-23 |
Schering Ag |
New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
|
WO1998008849A1
(en)
*
|
1996-08-30 |
1998-03-05 |
Novartis Aktiengesellschaft |
Method for producing epothilones, and intermediate products obtained during the production process
|
EP0941227B2
(en)
*
|
1996-11-18 |
2009-10-14 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Epothilone d, production process, and its use as cytostatic as well as phytosanitary agent
|
US6242469B1
(en)
|
1996-12-03 |
2001-06-05 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
US6441186B1
(en)
*
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
DK0975638T3
(en)
*
|
1997-02-25 |
2002-11-18 |
Biotechnolog Forschung Gmbh |
Side-chain modified epothilones
|
US6605599B1
(en)
*
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
DK1005465T3
(en)
|
1997-08-09 |
2007-11-05 |
Bayer Schering Pharma Ag |
New epothilone derivatives, processes for their preparation and their pharmaceutical use
|
US6320045B1
(en)
|
1997-12-04 |
2001-11-20 |
Bristol-Myers Squibb Company |
Process for the reduction of oxiranyl epothilones to olefinic epothilones
|
WO1999028324A1
(en)
*
|
1997-12-04 |
1999-06-10 |
Bristol-Myers Squibb Company |
A process for the reduction of oxiranyl epothilones to olefinic epothilones
|
US6365749B1
(en)
*
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
MXPA00007681A
(en)
*
|
1998-02-05 |
2003-07-14 |
Novartis Ag |
Compositions containing organic compounds.
|
GB9802451D0
(en)
*
|
1998-02-05 |
1998-04-01 |
Ciba Geigy Ag |
Organic compounds
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
FR2775187B1
(en)
*
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
|
US6302838B1
(en)
|
1998-02-25 |
2001-10-16 |
Novartis Ag |
Cancer treatment with epothilones
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
US6380395B1
(en)
*
|
1998-04-21 |
2002-04-30 |
Bristol-Myers Squibb Company |
12, 13-cyclopropane epothilone derivatives
|
DE19820599A1
(en)
*
|
1998-05-08 |
1999-11-11 |
Biotechnolog Forschung Gmbh |
New epothilone derivatives useful as pharmaceuticals and in plant protection
|
US6121029A
(en)
|
1998-06-18 |
2000-09-19 |
Novartis Ag |
Genes for the biosynthesis of epothilones
|
SI0987268T1
(en)
*
|
1998-08-05 |
2002-10-31 |
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) |
Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide
|
DE19848306A1
(en)
|
1998-10-14 |
2000-04-20 |
Schering Ag |
High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates
|
KR100851418B1
(en)
|
1998-11-20 |
2008-08-08 |
코산 바이오사이언시즈, 인코포레이티드 |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
US6780620B1
(en)
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
PL350190A1
(en)
|
1999-02-11 |
2002-11-18 |
Schering Ag |
Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
|
DE60006649T2
(en)
|
1999-02-22 |
2004-09-30 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
C-21 MODIFIED EPOTHILONE
|
US6291684B1
(en)
|
1999-03-29 |
2001-09-18 |
Bristol-Myers Squibb Company |
Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
EP3222619A1
(en)
|
1999-04-15 |
2017-09-27 |
Bristol-Myers Squibb Holdings Ireland |
Cyclic protein tyrosine kinase inhibitors
|
US7125893B1
(en)
|
1999-04-30 |
2006-10-24 |
Schering Ag |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
GB0003753D0
(en)
*
|
2000-02-17 |
2000-04-05 |
Biochemie Gmbh |
Organic compounds
|
US20020077290A1
(en)
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
US6518421B1
(en)
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
US6593115B2
(en)
|
2000-03-24 |
2003-07-15 |
Bristol-Myers Squibb Co. |
Preparation of epothilone intermediates
|
US6589968B2
(en)
|
2001-02-13 |
2003-07-08 |
Kosan Biosciences, Inc. |
Epothilone compounds and methods for making and using the same
|
UA75365C2
(en)
*
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
ES2395895T3
(en)
|
2000-09-22 |
2013-02-15 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Triazolo-epothilones
|
GB0029895D0
(en)
|
2000-12-07 |
2001-01-24 |
Novartis Ag |
Organic compounds
|
BR0206511A
(en)
|
2001-01-25 |
2003-10-21 |
Bristol Myeres Squibb Company |
Parenteral formulation for epothilone analogs
|
PT1353668E
(en)
|
2001-01-25 |
2008-06-30 |
Bristol Myers Squibb Co |
Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
|
WO2002058699A1
(en)
*
|
2001-01-25 |
2002-08-01 |
Bristol-Myers Squibb Company |
Pharmaceutical forms of epothilones for oral administration
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
EE200300396A
(en)
|
2001-02-20 |
2003-12-15 |
Bristol-Myers Squibb Company |
Use of epothilone derivatives for the treatment of refractory tumors
|
PL363363A1
(en)
|
2001-02-20 |
2004-11-15 |
Bristol-Myers Squibb Company |
Epothilone derivatives for the treatment of refractory tumors
|
ES2326264T3
(en)
|
2001-02-27 |
2009-10-06 |
Novartis Ag |
COMBINATION THAT INCLUDES A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTILONE DERIVATIVE.
|
BRPI0207961B8
(en)
|
2001-03-14 |
2021-05-25 |
Bristol Myers Squibb Co |
use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds.
|
CA2449077A1
(en)
|
2001-06-01 |
2002-12-12 |
Gregory D. Vite |
Epothilone derivatives
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
US6884608B2
(en)
|
2001-12-26 |
2005-04-26 |
Bristol-Myers Squibb Company |
Compositions and methods for hydroxylating epothilones
|
BR0306861A
(en)
|
2002-01-14 |
2004-11-03 |
Novartis Ag |
Combinations comprising epothilones and antimetabolites
|
US6719540B2
(en)
|
2002-03-12 |
2004-04-13 |
Bristol-Myers Squibb Company |
C3-cyano epothilone derivatives
|
WO2003077903A1
(en)
|
2002-03-12 |
2003-09-25 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
WO2003105828A1
(en)
|
2002-06-14 |
2003-12-24 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
CA2496477C
(en)
|
2002-08-23 |
2012-10-16 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
RS20050235A
(en)
*
|
2002-09-23 |
2007-06-04 |
Bristol Myers Squibb Company, |
Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
Open chain prolyl urea-related modulators of androgen receptor function
|
DE10344882A1
(en)
*
|
2003-09-26 |
2005-04-21 |
Morphochem Ag Komb Chemie |
New macrocycles for the treatment of cancer
|
US20050171167A1
(en)
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
DE10355223A1
(en)
*
|
2003-11-26 |
2005-06-30 |
Institut für Pflanzenbiochemie (IPB) |
New macrocycles for the treatment of cancer
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US20060121511A1
(en)
|
2004-11-30 |
2006-06-08 |
Hyerim Lee |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
CN1312286C
(en)
*
|
2005-10-19 |
2007-04-25 |
华南理工大学 |
Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum
|
US20110104664A1
(en)
|
2006-03-31 |
2011-05-05 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
|
AU2007329375A1
(en)
|
2006-12-04 |
2008-06-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
|
WO2008147941A1
(en)
|
2007-05-25 |
2008-12-04 |
Bristol-Myers Squibb Company |
Processes for making epothilone compounds and analogs
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
DE102007059752A1
(en)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Functionalized solid polymer nanoparticles containing epothilones
|
CN101918400B
(en)
*
|
2008-02-01 |
2012-08-29 |
浙江海正药业股份有限公司 |
A method for the separation and purification of epothilones
|
CN101362784A
(en)
*
|
2008-10-06 |
2009-02-11 |
山东大学 |
Ebomycin glycosides compounds, composition using the same as activity component and use thereof
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treatment of autoimmune and other diseases
|
US8618146B2
(en)
|
2011-01-03 |
2013-12-31 |
Dr. Reddy's Laboratories Limited |
Epothilone compound formulations
|
CN102863474A
(en)
|
2011-07-09 |
2013-01-09 |
陈小平 |
Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
|
CN102993239A
(en)
|
2011-09-19 |
2013-03-27 |
陈小平 |
Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
|
WO2014075391A1
(en)
|
2012-11-17 |
2014-05-22 |
北京市丰硕维康技术开发有限责任公司 |
Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
|
CN103145722B
(en)
*
|
2013-03-05 |
2015-12-02 |
福建省微生物研究所 |
A kind of method of high speed adverse current chromatogram separating-purifying ebormycine
|
US20160185793A1
(en)
*
|
2013-08-19 |
2016-06-30 |
Sandoz Ag |
Method for the purification of epothilones via crystallization
|